AstraZeneca Promises 10 New Drugs By 2020
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CEO Pascal Soriot said the big pharma is on track to return to growth faster than anticipated, with 2017 revenues expected to be in line with 2013. A key driver of growth will be new drugs, many of which have been gained through deal-making and acquisitions.